Antihypoxic oxygenation agents with respiratory hyperoxia to improve cancer immunotherapy

Hypoxia-inducible factors in physiology and medicine

Semenza, G. L. (2012) · Cell · doi:10.1016/j.cell.2012.01.021 · Cited by 3,645 · see citing works

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088 · see citing works

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

Rosenberg, S. A., Restifo, N. P., Yang, J. C.-H., Morgan, R. A., & Dudley, M. E. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2355 · Cited by 1,654 · see citing works

CD8+ T cell states in human cancer: insights from single-cell analysis

van der Leun, A. M., Thommen, D. S., & Schumacher, T. N. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-019-0235-4 · Cited by 1,439 · see citing works

Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage

Ohta, A., & Sitkovsky, M. V. (2001) · Nature · doi:10.1038/414916a · Cited by 1,336 · see citing works

A2A adenosine receptor protects tumors from antitumor T cells

Ohta, A., Gorelik, E., Prasad, S. J., Ronchese, F., Lukashev, D. E., Wong, M. K. K., Huang, X., Caldwell, S. A., Liu, K., Smith, P. T., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605251103 · Cited by 1,066 · see citing works

Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response

Dewhirst, M. W., Cao, Y., & Moeller, B. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2397 · Cited by 1,022 · see citing works

Hypoxia-Inducible Factors: Master Regulators of Cancer Progression

Schito, L., & Semenza, G. L. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.10.016 · Cited by 962 · see citing works

CAR T Cell Therapy for Solid Tumors

Newick, K., O'Brien, S., Moon, E., & Albelda, S. M. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-062315-120245 · Cited by 909 · see citing works

Adenosine receptors as drug targets — what are the challenges?

Chen, J., Eltzschig, H. K., & Fredholm, B. B. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3955 · Cited by 899 · see citing works

The Basis of Oncoimmunology

Palucka, A. K., & Coussens, L. M. (2016) · Cell · doi:10.1016/j.cell.2016.01.049 · Cited by 843 · see citing works

Immunity, inflammation and cancer: a leading role for adenosine

Antonioli, L., Blandizzi, C., Pacher, P., & Haskó, G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3613 · Cited by 765 · see citing works

P hysiological C ontrol of I mmune R esponse and I nflammatory T issue D amage by H ypoxia -I nducible F actors and A denosine A 2A R eceptors

Sitkovsky, M. V., Lukashev, D. E., Apasov, S. G., Kojima, H., Koshiba, M., Caldwell, C. C., Ohta, A., & Thiel, M. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104731 · Cited by 697 · see citing works

Ecto-5′-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia

Synnestvedt, K., Furuta, G. T., Comerford, K. M., Louis, N. A., Karhausen, J., Eltzschig, H. K., Hansen, K. R., Thompson, L. F., & Colgan, S. P. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15337 · Cited by 679 · see citing works

Purinergic Signaling during Inflammation

Eltzschig, H. K., Mv, S., & Robson, S. C. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1300259 · Cited by 608 · see citing works

Immunological mechanisms of the antitumor effects of supplemental oxygenation

Hatfield, S. M., Kjaergaard, J., Lukashev, D., Schreiber, T. H., Belikoff, B., Abbott, R., Sethumadhavan, S., Philbrook, P., Ko, K., Cannici, R., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa1260 · Cited by 600 · see citing works

The importance of exosomal PDL1 in tumour immune evasion

Daassi, D., Mahoney, K. M., & Freeman, G. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0264-y · Cited by 598 · see citing works

Identification and Characterization of CD39/Vascular ATP Diphosphohydrolase

Kaczmarek, E., Koziak, K., Sévigny, J., Siegel, J. B., Anrather, J., Beaudoin, A. R., Bach, F. H., & Robson, S. C. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.51.33116 · Cited by 582 · see citing works

Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis

Stagg, J., Divisekera, U., McLaughlin, N. M., Sharkey, J., Pommey, S., Denoyer, D., Dwyer, K. M., & Smyth, M. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908801107 · Cited by 570 · see citing works

Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice

Haskó, G., Szabó, C., Nemeth, Z. H., Kvetan, V., Pastores, S. M., & Vizi, E. S. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.10.4634 · Cited by 536 · see citing works

Role of A2a Extracellular Adenosine Receptor-Mediated Signaling in Adenosine-Mediated Inhibition of T-Cell Activation and Expansion

Huang, S., Apasov, S., Koshiba, M., & Sitkovsky, M. (1997) · Blood · doi:10.1182/blood.v90.4.1600 · Cited by 531 · see citing works

An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression

Palazon, A., Tyrakis, P. A., Macias, D., Veliça, P., Rundqvist, H., Fitzpatrick, S., Vojnovic, N., Phan, A. T., Loman, N., Hedenfalk, I., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.003 · Cited by 521 · cited 4× · see citing works

Regulation of immune cells by local-tissue oxygen tension: HIF1α and adenosine receptors

Sitkovsky, M., & Lukashev, D. (2005) · Nature Reviews Immunology · doi:10.1038/nri1685 · Cited by 518 · see citing works

A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells

Zarek, P. E., Huang, C.-T., Lutz, E. R., Kowalski, J., Horton, M. R., Linden, J. M., Drake, C. G., & Powell, J. D. (2007) · Blood · doi:10.1182/blood-2007-03-081646 · Cited by 516 · see citing works

CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer

Loi, S., Pommey, S., Haibe‐Kains, B., Beavis, P. A., Darcy, P. K., Smyth, M. J., & Stagg, J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222251110 · Cited by 497 · see citing works

Physiological roles for ecto-5’-nucleotidase (CD73)

Colgan, S. P., Eltzschig, H. K., Eckle, T. D. L. G., & Thompson, L. F. (2006) · Purinergic Signalling · doi:10.1007/s11302-005-5302-5 · Cited by 496 · see citing works

CD73 on Tumor Cells Impairs Antitumor T-Cell Responses: A Novel Mechanism of Tumor-Induced Immune Suppression

Jin, D., Fan, J., Wang, L., Thompson, L. F., Liu, A., Daniel, B. J., Shin, T., Curiel, T. J., & Zhang, B. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3109 · Cited by 433 · see citing works

Differential Effects of Physiologically Relevant Hypoxic Conditions on T Lymphocyte Development and Effector Functions

Caldwell, C. C., Kojima, H., Lukashev, D., Armstrong, J., Farber, M., Apasov, S. G., & Sitkovsky, M. V. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.11.6140 · Cited by 420 · see citing works

Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy

Jayaprakash, P., Ai, M., Liu, A., Budhani, P., Bartkowiak, T., Sheng, J., Ager, C., Nicholas, C., Jaiswal, A. R., Sun, Y., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96268 · Cited by 399 · see citing works

Cellular and Humoral immunity to Different Types of Human Neoplasms

Hellström, I., Hellström, K. E., Pierce, G. E., & Yang, J. P. S. (1968) · Nature · doi:10.1038/2201352a0 · Cited by 394 · see citing works

Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses

Young, A., Ngiow, S. F., Barkauskas, D. S., Sult, E., Hay, C. M., Blake, S. J., Huang, Q., Liu, J., Takeda, K., Teng, M. W. L., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.025 · Cited by 389 · see citing works

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer

Fong, L., Hotson, A., Powderly, J. D., Sznol, M., Heist, R. S., Choueiri, T. K., George, S., Hughes, B. G. M., Hellmann, M. D., Shepard, D. R., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0980 · Cited by 352 · see citing works

Blockade of A 2A receptors potently suppresses the metastasis of CD73 + tumors

Beavis, P. A., Divisekera, U., Paget, C., Chow, M. T., John, L. B., Devaud, C., Dwyer, K. M., Stagg, J., Smyth, M. J., & Darcy, P. K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1308209110 · Cited by 346 · see citing works

Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses

Beavis, P. A., Milenkovski, N., Henderson, M. A., John, L. B., Allard, B., Loi, S., Kershaw, M. H., Stagg, J., & Darcy, P. K. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0211 · Cited by 331 · see citing works

Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy

Beavis, P. A., Henderson, M. A., Giuffrida, L., Mills, J. K., Sek, K., Cross, R. S., Davenport, A. J., John, L. B., Mardiana, S., Slaney, C. Y., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89455 · Cited by 326 · see citing works

Germinal centre hypoxia and regulation of antibody qualities by a hypoxia response system

Cho, S. H., Raybuck, A. L., Stengel, K. R., Wei, M., Beck, T. C., Volanakis, E. J., Thomas, J. W., Hiebert, S. W., Haase, V. H., & Boothby, M. R. (2016) · Nature · doi:10.1038/nature19334 · Cited by 307 · see citing works

Pharmacologic Targeting of Hypoxia-Inducible Factors

Semenza, G. L. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021637 · Cited by 288 · see citing works

Oxygenation Inhibits the Physiological Tissue-Protecting Mechanism and Thereby Exacerbates Acute Inflammatory Lung Injury

Thiel, M., Choukèr, A., Ohta, A., Jackson, E., Caldwell, C. C., Smith, P. T., Lukashev, D. E., Bittmann, I., & Sitkovsky, M. V. (2005) · PLoS Biology · doi:10.1371/journal.pbio.0030174 · Cited by 287 · see citing works

CD39/ENTPD1 Expression by CD4+Foxp3+ Regulatory T Cells Promotes Hepatic Metastatic Tumor Growth in Mice

Sun, X., Wu, Y., Gao, W., Enjyoji, K., Csizmadia, E., Müller, C. E., Murakami, T., & Robson, S. C. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.05.007 · Cited by 279 · see citing works

The EGLN-HIF O 2 -Sensing System: Multiple Inputs and Feedbacks

Ivan, M., & Kaelin, W. G. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.06.002 · Cited by 273 · see citing works

Identification of Ectonucleotidases CD39 and CD73 in Innate Protection during Acute Lung Injury

Eckle, T. D. L. G., Füllbier, L., Wehrmann, M., Khoury, J., Mittelbronn, M. G. A., Ibla, J. C., Rosenberger, P., & Eltzschig, H. K. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.12.8127 · Cited by 267 · see citing works

Hypoxia-Adenosinergic Immunosuppression: Tumor Protection by T Regulatory Cells and Cancerous Tissue Hypoxia

Sitkovsky, M. V., Kjaergaard, J., Lukashev, D., & Ohta, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0229 · Cited by 253 · see citing works

Abnormal B lymphocyte development and autoimmunity in hypoxia-inducible factor 1α-deficient chimeric mice

Kojima, H., Gu, H., Nomura, S., Caldwell, C. C., Kobata, T., Carmeliet, P., Semenza, G. L., & Sitkovsky, M. V. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.052706699 · Cited by 224 · see citing works

Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis

Wong, C. C., Zhang, H., Gilkes, D. M., Chen, J., Wei, H., Chaturvedi, P., Hubbi, M. E., & Semenza, G. L. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0855-y · Cited by 224 · see citing works

A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti–PD-(L)1 and Anti–CTLA-4 in Preclinical Models

Willingham, S. B., Ho, P. Y., Hotson, A. N., Hill, C. M., Piccione, E. C., Hsieh, J. Y., Liu, L., Buggy, J. J., McCaffery, I., & Miller, R. A. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0056 · Cited by 221 · see citing works

Hostile, Hypoxia–A2-Adenosinergic Tumor Biology as the Next Barrier to Overcome for Tumor Immunologists

Sitkovsky, M. V., Hatfield, S., Abbott, R., Belikoff, B., Lukashev, D., & Ohta, A. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0075 · Cited by 215 · see citing works

Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1α-dependent and extracellular adenosine-mediated tumor protection

Hatfield, S. M., Kjaergaard, J., Lukashev, D., Belikoff, B., Schreiber, T. H., Sethumadhavan, S., Abbott, R., Philbrook, P., Thayer, M., Shujia, D., et al. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1189-3 · Cited by 211 · see citing works

Cutting Edge: Hypoxia-Inducible Factor 1α and Its Activation-Inducible Short Isoform I.1 Negatively Regulate Functions of CD4+ and CD8+ T Lymphocytes

Lukashev, D., Klebanov, B., Kojima, H., Grinberg, A., Ohta, A., Berenfeld, L., Wenger, R. H., Ohta, A., & Sitkovsky, M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.8.4962 · Cited by 208 · see citing works

T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response

Sitkovsky, M. V. (2009) · Trends in Immunology · doi:10.1016/j.it.2008.12.002 · Cited by 192 · see citing works

Current issues and perspectives in PD-1 blockade cancer immunotherapy

Chamoto, K., Hatae, R., & Honjo, T. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01588-7 · Cited by 180 · see citing works

Targeted Deletion of HIF-1α Gene in T Cells Prevents their Inhibition in Hypoxic Inflamed Tissues and Improves Septic Mice Survival

Thiel, M., Caldwell, C. C., Kreth, S., Kuboki, S., Chen, P., Smith, P., Ohta, A., Lentsch, A. B., Lukashev, D., & Sitkovsky, M. V. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000853 · Cited by 175 · see citing works

Exocytosis of cytolytic granules may not be required for target cell lysis by cytotoxic T-lymphocytes

Trenn, G., Takayama, H., & Sitkovsky, M. V. (1987) · Nature · doi:10.1038/330072a0 · Cited by 171 · see citing works

Patterns of A2A Extracellular Adenosine Receptor Expression in Different Functional Subsets of Human Peripheral T Cells. Flow Cytometry Studies with Anti-A2A Receptor Monoclonal Antibodies

Koshiba, M., Rosin, D. L., Hayashi, N., Linden, J. M., & Sitkovsky, M. V. (1999) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12188-8 · Cited by 170 · see citing works

Contribution of E‐NTPDasel (CD39) to renal protection from ischemia‐reperfusion injury

Grenz, A., Zhang, H., Hermes, M., Eckle, T. D. L. G., Klingel, K., Huang, D. Y., Müller, C. E., Robson, S. C., Oßwald, H., & Eltzschig, H. K. (2007) · The FASEB Journal · doi:10.1096/fj.06-7947com · Cited by 154 · see citing works

Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor

Waickman, A. T., Alme, A., Senaldi, L., Zarek, P. E., Horton, M. R., & Powell, J. D. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1155-7 · Cited by 151 · see citing works

Cancer Immunotherapy: Beyond Checkpoint Blockade

Dougan, M. L., Dranoff, G., & Dougan, S. K. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055552 · Cited by 147 · see citing works

Hypoxia-inducible factors in CD4 + T cells promote metabolism, switch cytokine secretion, and T cell help in humoral immunity

Cho, S. H., Raybuck, A. L., Blagih, J., Kemboi, E., Haase, V. H., Jones, R. G., & Boothby, M. R. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1811702116 · Cited by 138 · see citing works

A2A Adenosine Receptor Gene Deletion or Synthetic A2A Antagonist Liberate Tumor-Reactive CD8+ T Cells from Tumor-Induced Immunosuppression

Kjaergaard, J., Hatfield, S., Jones, G., Ohta, A., & Sitkovsky, M. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1700850 · Cited by 132 · see citing works

Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment

Lan, J., Lu, H., Samanta, D., Salman, S., Lü, Y., & Semenza, G. L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1809695115 · Cited by 127 · see citing works

Antigen receptor-regulated exocytosis in cytotoxic T lymphocytes.

Takayama, H., & Sitkovsky, M. V. (1987) · The Journal of Experimental Medicine · doi:10.1084/jem.166.3.725 · Cited by 125 · see citing works

Hypoxia and hypoxia-inducible factor (HIF) downregulate antigen-presenting MHC class I molecules limiting tumor cell recognition by T cells

Sethumadhavan, S., Silva, M., Philbrook, P., Nguyen, T., Hatfield, S. M., Ohta, A., & Sitkovsky, M. V. (2017) · PLOS ONE · doi:10.1371/journal.pone.0187314 · Cited by 119 · see citing works

Germinal Center Hypoxia Potentiates Immunoglobulin Class Switch Recombination

Abbott, R. K., Thayer, M., Labuda, J. C., Silva, M., Philbrook, P., Cain, D. W., Kojima, H., Hatfield, S. M., Sethumadhavan, S., Ohta, A., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1601401 · Cited by 113 · see citing works

Protein kinase A–dependent phosphorylation stimulates the transcriptional activity of hypoxia-inducible factor 1

Bullen, J. W., Tchernyshyov, I., Holewinski, R. J., Devine, L. R., Wu, F., Venkatraman, V., KASS, D., Cole, R. N., Eyk, J. E. V., & Semenza, G. L. (2016) · Science Signaling · doi:10.1126/scisignal.aaf0583 · Cited by 107 · see citing works

Hypoxia-dependent anti-inflammatory pathways in protection of cancerous tissues

Lukashev, D. E., Ohta, A., & Sitkovsky, M. V. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9054-2 · Cited by 103 · see citing works

Differentiation Stage-Specific Requirement in Hypoxia-Inducible Factor-1α–Regulated Glycolytic Pathway during Murine B Cell Development in Bone Marrow

Kojima, H., Kobayashi, A., Sakurai, D., Kanno, Y., Hase, H., Takahashi, R., Totsuka, Y., Semenza, G. L., Sitkovsky, M. V., & Kobata, T. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0800167 · Cited by 99 · see citing works

Differential Regulation of Two Alternatively Spliced Isoforms of Hypoxia-inducible Factor-1α in Activated T Lymphocytes

Lukashev, D. E., Caldwell, C. C., Ohta, A., Chen, P., & Sitkovsky, M. V. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104782200 · Cited by 97 · see citing works

In vivo T Cell Activation in Lymphoid Tissues is Inhibited in the Oxygen-Poor Microenvironment

Ohta, A., Diwanji, R., Kini, R., Subramanian, M., Ohta, A., & Sitkovsky, M. V. (2011) · Frontiers in Immunology · doi:10.3389/fimmu.2011.00027 · Cited by 86 · see citing works

Gene dose effect reveals no Gs-coupled A2A adenosine receptor reserve in murine T-lymphocytes: studies of cells from A2A-receptor-gene-deficient mice

Armstrong, J. M., Chen, J., Schwarzschild, M. A., Apasov, S. G., Smith, P. T., Caldwell, C. C., Pearl, C. H. E. N., Figler, H., Sullivan, G. W., Steven, F. I. N. K., et al. (2001) · Biochemical Journal · doi:10.1042/0264-6021:3540123 · Cited by 76 · see citing works

Lessons from the A2A Adenosine Receptor Antagonist–Enabled Tumor Regression and Survival in Patients with Treatment-Refractory Renal Cell Cancer

Sitkovsky, M. V. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1280 · Cited by 76 · see citing works

Effects of extracellular ATP and adenosine on different thymocyte subsets: possible role of ATP-gated channels and G protein-coupled purinergic receptor

Apasov, S. G., Koshiba, M., Chused, T. M., & Sitkovsky, M. V. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.11.5095 · Cited by 75 · see citing works

Adenosine and the Regulation of Metabolism and Body Temperature

Fredholm, B. B., Johansson, S. M., & Wang, Y.-Q. (2011) · Advances in pharmacology · doi:10.1016/b978-0-12-385526-8.00003-5 · Cited by 69 · see citing works

A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies

Hegde, A. M., Jayaprakash, P., Couillault, C., Piha-Paul, S. A., Karp, D. D., Rodon, J. A., Pant, S., Fu, S., Dumbrava, E. E. I., Yap, T. A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4118 · Cited by 62 · see citing works

Critical Role of Hypoxia and A2A Adenosine Receptors in Liver Tissue-Protecting Physiological Anti-Inflammatory Pathway

Choukèr, A., Thiel, M., Lukashev, D. E., Ward, J. M., Kaufmann, I., Apasov, S. G., Sitkovsky, M. V., & Ohta, A. (2008) · Molecular Medicine · doi:10.2119/2007-00075.chouker · Cited by 59 · see citing works

Differential regulation of HIF-1α isoforms in murine macrophages by TLR4 and adenosine A2A receptor agonists

Ramanathan, M., Luo, W., Csóka, B., Haskó, G., Lukashev, D. E., Sitkovsky, M. V., & Leibovich, S. J. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0109021 · Cited by 50 · see citing works

Targeting the hypoxia-adenosinergic signaling pathway to improve the adoptive immunotherapy of cancer

Sitkovsky, M. V., & Ohta, A. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1001-9 · Cited by 49 · see citing works

In Vivo Hypoxic Preconditioning Protects From Warm Liver Ischemia-Reperfusion Injury Through the Adenosine A2B Receptor

Choukèr, A., Ohta, A., Martignoni, A., Lukashev, D. E., Zacharia, L. C., Jackson, E. K., Schnermann, J. B., Ward, J. M., Kaufmann, I., Klaunberg, B. A., et al. (2012) · Transplantation · doi:10.1097/tp.0b013e31826a9a46 · Cited by 47 · see citing works

Hypoxia-induced and A2A adenosine receptor-independent T-cell suppression is short lived and easily reversible

Ohta, A., Madasu, M. M., Subramanian, M., Kini, R., Jones, G. B., Choukèr, A., Ohta, A., & Sitkovsky, M. V. (2013) · International Immunology · doi:10.1093/intimm/dxt045 · Cited by 44 · see citing works

Blood substitutes

Winslow, R. M. (2002) · Current Opinion in Hematology · doi:10.1097/00062752-200203000-00011 · Cited by 40 · see citing works

Phosphodiesterases as Targets for Modulating T-Cell Responses

Bjørgo, E., Moltu, K., & Taskén, K. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-17969-3_15 · Cited by 36 · see citing works

Sphingosine-1-Phosphate Reduces CD4+ T-Cell Activation in Type 1 Diabetes Through Regulation of Hypoxia-Inducible Factor Short Isoform I.1 and CD69

Srinivasan, S. R., Bolick, D. T., Lukashev, D. E., Lappas, C. M., Sitkovsky, M. V., Lynch, K. R., & Hedrick, C. C. (2007) · Diabetes · doi:10.2337/db07-0855 · Cited by 36 · see citing works

Mechanistic, Functional and Immunopharmacological Implications of Biochemical Studies of Antigen Receptor‐Triggered Cytolytic T‐Lymphocyte Activation*

Sitkovsk, M. V. (1988) · Immunological Reviews · doi:10.1111/j.1600-065x.1988.tb00754.x · Cited by 34 · see citing works

Oxygenation to improve cancer vaccines, adoptive cell transfer and blockade of immunological negative regulators

Hatfield, S. M., & Sitkovsky, M. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1052934 · Cited by 31 · see citing works

In vitroinduction of T cells that are resistant to A2adenosine receptor‐mediated immunosuppression

Ohta, A., Kjærgaard, J., Sharma, S., Mohsin, M., Goel, N., Madasu, M. M., Fradkov, E., Akiko, O., & Sitkovsky, M. V. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00019.x · Cited by 25 · see citing works

Preferential expression of the novel alternative isoform I.3 of hypoxia-inducible factor 1α in activated human T lymphocytes

Lukashev, D., & Sitkovsky, M. (2008) · Human Immunology · doi:10.1016/j.humimm.2008.05.004 · Cited by 25 · see citing works

From the Hellstrom paradox toward cancer cure

Hellström, K. E., & Hellström, I. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2018.11.002 · Cited by 22 · see citing works

Postoperative Hyperoxia (60%) Worsens Hepatic Injury in Mice

Zangl, Q., Martignoni, A., Jackson, S. H., Ohta, A., Klaunberg, B. A., Kaufmann, I., Lukashev, D. E., Ward, J. M., Sitkovsky, M. V., Thiel, M., et al. (2014) · Anesthesiology · doi:10.1097/aln.0000000000000447 · Cited by 20 · see citing works

Cyclic AMP‐Dependent Protein Kinase as a Part of the Possible Down‐regulating Pathway in the Antigen Receptor‐Regulated Cytotoxic T Lymphocyte Conjugate Formation and Granule Exocytosis

Sitkovsky, M. V., Trenn, G., & TAKAYAMA, H. (1988) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1988.tb36352.x · Cited by 19 · see citing works

A2Ablockade enhances anti-metastatic immune responses

Beavis, P. A., Milenkovski, N., Stagg, J., Smyth, M. J., & Darcy, P. K. (2013) · OncoImmunology · doi:10.4161/onci.26705 · Cited by 18 · see citing works

Genetic deletion of the HIF ‐1α isoform I.1 in T cells enhances antibacterial immunity and improves survival in a murine peritonitis model

Georgiev, P., Belikoff, B. G., Hatfield, S. M., Ohta, A., Sitkovsky, M. V., & Lukashev, D. E. (2012) · European Journal of Immunology · doi:10.1002/eji.201242765 · Cited by 17 · see citing works

Gene dose effect reveals no Gs-coupled A2A adenosine receptor reserve in murine T-lymphocytes: studies of cells from A2A-receptor-gene-deficient mice

ARMSTRONG, J. M., Jiang Fan, C. H. E. N., SCHWARZSCHILD, M. A., APASOV, S., SMITH, P. T., CALDWELL, C., Pearl, C. H. E. N., FIGLER, H., SULLIVAN, G., Steven, F. I. N. K., et al. (2001) · Biochemical Journal · doi:10.1042/bj3540123

Hypoxia-inducible factors: cancer progression and clinical translation

Wicks, E. E., & Semenza, G. L. (2022) · Journal of Clinical Investigation · doi:10.1172/jci159839 · Cited by 600 · see citing works

Therapeutic targeting of the hypoxic tumour microenvironment

Singleton, D. C., Macann, A., & Wilson, W. R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00539-4 · Cited by 493 · see citing works

Immunotherapy: Reshape the Tumor Immune Microenvironment

Bingzhe, L. V., Wang, Y., Ma, D., Cheng, W., Liu, J., Yong, T., Chen, H., & Wang, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844142 · Cited by 489 · see citing works

ATP and cancer immunosurveillance

Kepp, O., Bezu, L., Yamazaki, T., Virgilio, F. D., Smyth, M. J., Kroemer, G., & Galluzzi, L. (2021) · The EMBO Journal · doi:10.15252/embj.2021108130 · Cited by 231 · see citing works

CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy

Giuffrida, L., Sek, K., Henderson, M. A., Lai, J., Chen, A. X. Y., Meyran, D., Todd, K. L., Petley, E. V., Mardiana, S., Mølck, C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23331-5 · Cited by 233 · see citing works

Advances in molecular pathology and therapy of non-small cell lung cancer

Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197 · see citing works

Adenosine-A2A Receptor Pathway in Cancer Immunotherapy

Sun, C., Wang, B., & Hao, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.837230 · Cited by 182 · see citing works

ATP and Adenosine Metabolism in Cancer: Exploitation for Therapeutic Gain

Yegutkin, G. G., & Boison, D. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000528 · Cited by 171 · see citing works

Hypoxia signaling in cancer: Implications for therapeutic interventions

Zhuang, Y., Liu, K., He, Q., Gu, X., Jiang, C., & Wu, J. (2023) · MedComm · doi:10.1002/mco2.203 · Cited by 119 · see citing works

HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy

Salman, S., Meyers, D. J., Wicks, E. E., Lee, S. N., Datan, E., Thomas, A. M., Anders, N. M., Hwang, Y., Lyu, Y., Yang, Y., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci156774 · Cited by 111 · see citing works

Hyperbaric Oxygen Boosts PD‐1 Antibody Delivery and T Cell Infiltration for Augmented Immune Responses Against Solid Tumors

Liu, X., Ye, N., Liu, S., Guan, J., Deng, Q., Zhang, Z., Xiao, C., Ding, Z., Zhang, B., Chen, X., et al. (2021) · Advanced Science · doi:10.1002/advs.202100233 · Cited by 83 · see citing works

The Synergistic Cooperation between TGF-β and Hypoxia in Cancer and Fibrosis

Mallikarjuna, P., Zhou, Y., & Landström, M. (2022) · Biomolecules · doi:10.3390/biom12050635 · Cited by 82 · see citing works

Engineering micro oxygen factories to slow tumour progression via hyperoxic microenvironments

Wang, W., Zheng, H., Jiang, J., Li, Z., Jiang, D., Shi, X., Wang, H., Jiang, J., Xie, Q., Gao, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32066-w · Cited by 81 · see citing works

Intratumoral hypoxia and mechanisms of immune evasion mediated by hypoxia-inducible factors

Semenza, G. L. (2021) · Physiology · doi:10.1152/physiol.00034.2020 · Cited by 64 · see citing works

Metabolic gatekeepers: harnessing tumor-derived metabolites to optimize T cell-based immunotherapy efficacy in the tumor microenvironment

Zheng, Y., Xu, R., Chen, X., Lu, Y., Zheng, J., Lin, Y., Lin, P., Zhao, X., & Cui, L. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07122-6 · Cited by 64 · see citing works

Arginase 1–Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize with Anti–PD-1 Checkpoint Blockade

Jørgensen, M. A., Ugel, S., Hübbe, M. L., Carretta, M., Perez-Penco, M., Weis-Banke, S. E., Martinenaite, E., Kopp, K., Chapellier, M., Adamo, A., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0280 · Cited by 61 · see citing works

Targeting Tumor Hypoxia with Nanoparticle-Based Therapies: Challenges, Opportunities, and Clinical Implications

Debnath, S. K., Debnath, M., Ghosh, A., Srivastava, R., & Omri, A. (2024) · Pharmaceuticals · doi:10.3390/ph17101389 · Cited by 51 · see citing works

Demethyleneberberine induces cell cycle arrest and cellular senescence of NSCLC cells via c-Myc/HIF-1α pathway

Liu, J., Huang, X., Liu, D., Ji, K., Tao, C., Zhang, R., & Chen, J. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153678 · Cited by 49 · see citing works

DLL1 orchestrates CD8 + T cells to induce long-term vascular normalization and tumor regression

Zhang, N., Yin, R., Zhou, P., Liu, X., Fan, P., Qian, L., Li, D., Zhang, C., Zheng, X., Deng, S., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2020057118 · Cited by 49 · see citing works

A macrophage membrane-coated mesoporous silica nanoplatform inhibiting adenosine A2AR via in situ oxygen supply for immunotherapy

Wen, X., Xiong, X., Yang, G., Xiao, W., Hou, J., Pan, T., Hu, Y., & Zhou, S. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.12.001 · Cited by 43 · see citing works

CD8+ T cells sustain antitumor response by mediating crosstalk between adenosine A2A receptor and glutathione/GPX4

Chen, S., Fan, J., Xie, P., Ahn, J., Fernandez, M., Billingham, L. K., Miska, J. M., Wu, J. D., Wainwright, D. A., Fang, D., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci170071 · Cited by 42 · see citing works

Protein kinase inhibitor ceritinib blocks ectonucleotidase CD39 – a promising target for cancer immunotherapy

Schäkel, L., Mirza, S., Winzer, R., Lopez, V., Idris, R. M., Al-Hroub, H., Pelletier, J., Sévigny, J., Tolosa, E., & Müller, C. E. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004660 · Cited by 34 · see citing works

HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy

Hussain, K., Liu, R., Smith, R. C. G., Müller, K. T. J., Ghorbani, M., Macari, S. A., Cleary, K. L. S., Oldham, R. J., Foxall, R. B., James, S., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02294-5 · Cited by 32 · see citing works

Glycoengineered anti-CD39 promotes anticancer responses by depleting suppressive cells and inhibiting angiogenesis in tumor models

Zhang, H., Feng, L., Mello, P. D. A., Mao, C., Near, R. I., Csizmadia, E., Chan, L. L., Enjyoji, K., Gao, W., Zhao, H., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci157431 · Cited by 31 · see citing works

Hyperoxia induces glucose metabolism reprogramming and intracellular acidification by suppressing MYC/MCT1 axis in lung cancer

Liu, X., Qin, H., Zhang, L., Jia, C., Chao, Z., Qin, X., Zhang, H., & Chen, C. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102647 · Cited by 28 · see citing works

Adenosine A2a receptor inhibition increases the anti-tumor efficacy of anti-PD1 treatment in murine hepatobiliary cancers

Myojin, Y., McCallen, J., Ma, C., Bauer, K. C., Ruf, B., Benmebarek, M.-R., Green, B. L., Wabitsch, S., McVey, J. C., Fu, C., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100959 · Cited by 27 · see citing works

Hypoxia-Induced Long Noncoding RNA HIF1A- AS2 Regulates Stability of MHC Class I Protein in Head and Neck Cancer

Liao, T., Chen, Y.-H., Li, Z.-Y., Hsiao, A.-C., Huang, Y.-L., Hao, R.-X., Tai, S., Chu, P., Shih, J.-W., Kung, H., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0622 · Cited by 26 · see citing works

Exploiting the tumor immune microenvironment and immunometabolism using mitochondria‐targeted drugs: Challenges and opportunities in racial disparity and cancer outcome research

Kalyanaraman, B. (2022) · The FASEB Journal · doi:10.1096/fj.202101862r · Cited by 23 · see citing works

Oxygen-carrying nanoemulsions and respiratory hyperoxia eliminate tumor hypoxia–induced immunosuppression

Halpin-Veszeleiova, K., Mallouh, M. P., Williamson, L. M., Apro, A. C., Botticello-Romero, N. R., Bahr, C., Shin, M., Ward, K. M., Rosenberg, L., Ritov, V. B., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.174675 · Cited by 22 · see citing works

Current Adenosinergic Therapies: What Do Cancer Cells Stand to Gain and Lose?

Kotulová, J., Hajdúch, M., & Džubák, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212569 · Cited by 21 · see citing works

Purinergic and Adenosinergic Signaling in Pancreatobiliary Diseases

Faraoni, E. Y., Ju, C., Robson, S. C., Eltzschig, H. K., & Bailey, J. M. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.849258 · Cited by 19 · see citing works

The Dual Effect of the BMP9–ALK1 Pathway in Blood Vessels: An Opportunity for Cancer Therapy Improvement?

Ayuso-Íñigo, B., Méndez-García, L., Pericacho, M., & Muñoz‐Félix, J. M. (2021) · Cancers · doi:10.3390/cancers13215412 · Cited by 19 · see citing works

Evaluation of Combination Strategies for the A2AR Inhibitor AZD4635 Across Tumor Microenvironment Conditions via a Systems Pharmacology Model

Voronova, V., Peskov, K. V., Kosinsky, Y., Helmlinger, G., Chu, L., Borodovsky, A., Woessner, R. D., Sachsenmeier, K. F., Shao, W., Kumar, R., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.617316 · Cited by 19 · see citing works

Adenosinergic Signaling as a Key Modulator of the Glioma Microenvironment and Reactive Astrocytes

Debom, G. N., Rubenich, D. S., & Braganhol, E. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.648476 · Cited by 19 · see citing works

Implications of Hyperoxia over the Tumor Microenvironment: An Overview Highlighting the Importance of the Immune System

Herrera-Campos, A. B., Zamudio-Martinez, E., Delgado-Bellido, D., Fernández-Cortés, M., Montuenga, L. M., Oliver, F. J., & Garcia-Diaz, A. (2022) · Cancers · doi:10.3390/cancers14112740 · Cited by 17 · see citing works

Anticoagulation therapy promotes the tumor immune-microenvironment and potentiates the efficacy of immunotherapy by alleviating hypoxia

Choi, J. U., Lee, N. K., Seo, H., Chung, S. W., Al-Hilal, T. A., Park, S. J., Kweon, S., Min, N., Kim, S. K., Ahn, S.-H., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002332 · Cited by 17 · see citing works

Breaking hypoxic barrier: Oxygen-supplied nanomaterials for enhanced T cell-mediated tumor immunotherapy

Xiang, S., Zhan, H., Zhan, J., Li, X., Lin, X., & Sun, W. (2025) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2025.100400 · Cited by 16 · see citing works

PDL1/HER2‐Targeted Lipid‐Encapsulated Oxygen Nanobubbles Combined with Photodynamic Therapy for HER2+ Breast Cancer Immunotherapy

Tian, J., Wan, S., Yang, Z., Wang, M., Zhou, W., Wo, G., Fu, S.-P., Zheng, S., Zhou, G., Hu, X., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202400030 · Cited by 16 · see citing works

Quantitative Analyses Reveal How Hypoxia Reconfigures the Proteome of Primary Cytotoxic T Lymphocytes

Ross, S. H., Rollings, C. M., & Cantrell, D. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.712402 · Cited by 16 · see citing works

Lactate signaling and immune suppression in tumors: mechanisms and therapeutic implications

Wang, X., Xiong, D., Cui, S., Duan, B., Ding, G., Huang, Y., & Wang, Q. (2026) · Cellular Oncology · doi:10.1007/s13402-026-01186-6 · Cited by 16 · see citing works

Turning Fluvastatin into a supramolecular immuno-sensitizer towards augmented tumor immunotherapy

Ma, F., Liu, T., Yang, W., You, W., He, W., Yan, J., & Liu, W. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.135310 · Cited by 15 · see citing works

Multiplex gene-editing strategy to engineer allogeneic EGFR-targeting CAR T-cells with improved efficacy against solid tumors

Murray, R. C., Chowdhury, M. R., Botticello-Romero, N. R., Desai, K., Chilakapati, S. R., Chong, B., Xia, Y., Messana, A., Sobon, H., Rocha, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66737-1 · Cited by 12 · see citing works

Gas-based therapeutics and delivery platforms in cancer immunotherapy

Nguyen, V.-A. T., Huang, C., & Chen, Y. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115746 · Cited by 11 · see citing works

A2AR eGFP reporter mouse enables elucidation of A2AR expression dynamics during anti-tumor immune responses

Todd, K. L., Lai, J., Sek, K., Huang, Y., Newman, D. M., Derrick, E. B., Koay, H., Nguyen, D. Q., Hoang, T. X., Petley, E. V., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42734-0 · Cited by 11 · see citing works

Therapeutic Targeting of Hypoxia-A2-Adenosinergic Pathway in COVID-19 Patients

Halpin-Veszeleiova, K., & Hatfield, S. M. (2021) · Physiology · doi:10.1152/physiol.00010.2021 · Cited by 10 · see citing works

Mismatch repair-proficient tumor footprints in the sands of immune desert: mechanistic constraints and precision platforms

Majumder, B., Nataraj, N. B., Maitreyi, L., & Datta, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1414376 · Cited by 10 · see citing works

Development of small molecule inhibitors of hypoxia-inducible factors for cancer therapy

Semenza, G. L. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100075 · Cited by 10 · see citing works

Suppressing the Hypoxia‐Adenosinergic Axis by a Tailored Nanoreactor for Enhanced Photothermal Immunotherapy

Gu, J., Chang, J., Chen, S., Zhi, H., Sun, J., Yin, W., Zhang, T., Zang, J., Zhao, Y., Liu, Y., et al. (2024) · Small Science · doi:10.1002/smsc.202300242 · Cited by 7 · see citing works

Pharmacologic HIF stabilization activates costimulatory receptor expression to increase antitumor efficacy of adoptive T cell therapy

Jackson, W., Yang, Y., Salman, S., Dordai, D. I., Lyu, Y., Datan, E., Drehmer, D., Huang, T. Y.-T., Hwang, Y., & Semenza, G. L. (2024) · Science Advances · doi:10.1126/sciadv.adq2366 · Cited by 7 · see citing works

HIF-1α Mediated Regulation of Glioblastoma Malignant Phenotypes through CD47 Protein: Understanding Functions and Mechanisms

Tan, Q., Li, F., Wang, J., Zou, Y., Tang, Y., Cai, Y.-Q., & Jiang, X. (2024) · Journal of Cancer · doi:10.7150/jca.101050 · Cited by 6 · see citing works

Baseline tumour vessel perfusion as a non-invasive predictive biomarker for immune checkpoint therapy in non-small-cell lung cancer

Liu, Z., Ma, K., Jia, Q., Yang, Y., Fan, P., Wang, Y., Wang, J., Sun, J., Sun, L., Shi, H., et al. (2024) · BMJ Oncology · doi:10.1136/bmjonc-2024-000473 · Cited by 6 · see citing works

The role of DLL1 in long-term vascular normalization and cancer immunotherapy

Wu, Q., & Huang, Y. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2021.0507 · Cited by 6 · see citing works

Adenosine receptors on the immuno-oncology expressway: TIME, perspectives, and translation

Majumder, B., & Datta, S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1676702 · Cited by 6 · see citing works

Vascular Normalization Was Associated with Colorectal Tumor Regression upon Anti-PD-L1 Combinational Therapy

Zhang, Y., Gao, J., He, Y., Qi, Z., Qian, L., Chen, W., Xu, H., Yue, Y., Mao, X., Guo, S., et al. (2023) · Journal of Immunology Research · doi:10.1155/2023/5867047 · Cited by 5 · see citing works

Integrated pan-cancer and melanoma-specific analysis of angiopoietin-2: prognostic value, immune microenvironment modulation, and ceRNA network regulation

Ni, X., Wan, X., Cai, B., Xie, H., Chen, L., Lin, Q., Ke, R., Huang, T., Ye, H., Shan, X., et al. (2025) · Discover Oncology · doi:10.1007/s12672-025-03448-5 · Cited by 4 · see citing works

Adenosine pathway inhibitors: novel investigational agents for the treatment of metastatic breast cancer

Rizzo, A., Massafra, R., Fanizzi, A., Rinaldi, L., Cusmai, A., Latorre, A. C., Zaccaria, G. M., Ronchi, M., Telegrafo, M., Gadaleta‐Caldarola, G., et al. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2078191 · Cited by 4 · see citing works

Purinergic Receptor Nanoimmunoamplifiers Potentiate Chemoimmunotherapy Efficacy in Hepatocellular Carcinoma

Zhang, J., Zhang, J., Feng, Q., Jiang, X. J., Yang, Y., Liu, W., Xiao, J., Feng, J., Wang, Z., Pan, M., et al. (2025) · Biomaterials Research · doi:10.34133/bmr.0278 · Cited by 3 · see citing works

Factors affecting prognosis in patients with locally advanced and advanced esophageal cancer receiving definitive radiotherapy in plateau regions

Zhang, J., Bai, H., Zhao, D., Hou, F., Lu, F., Xia, Y., & Wang, L. (2025) · Scientific Reports · doi:10.1038/s41598-025-86655-y · Cited by 3 · see citing works

The Role of Intra-Tumor Hypoxia in Cancer Cells Immune Escape Mechanism

Farhangnia, P., Delbandi, A., Aghamohamadi, N., Safdarian, A. R., & Akbarpour, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_61-1 · Cited by 3 · see citing works

First identification of potential bioactive compounds from ethanol extracts of Lepista sordida from Indonesia

Nurhayat, O. D., Putra, I. P., Sibero, M. T., Hermawan, R., Karimah, S. N., Anita, S. H., Yanto, D. H. Y., & Kristanto, M. A. (2023) · IOP Conference Series Earth and Environmental Science · doi:10.1088/1755-1315/1271/1/012058 · Cited by 2 · see citing works

Comprehensive genome editing confers ‘off-the-shelf’ CAR-T cells superior efficacy against solid tumorsPreprint

Murray, R. C., Navarrete, N. R. R., Desai, K., Chowdhury, M. R., Chilakapati, S. R., Chong, B., Messana, A., Sobon, H., Rocha, J., Musenge, F. M., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.03.551705 · Cited by 2 · see citing works

The Role of Intra-tumor Hypoxia in Cancer Cells Immune Escape Mechanism

Farhangnia, P., Delbandi, A., Aghamohamadi, N., Safdarian, A. R., & Akbarpour, M. (2025) · Springer eBooks · doi:10.1007/978-3-032-00759-9_61 · Cited by 1 · see citing works

Bioengineered cryogels overcome hypoxia-driven tolerance and restore antitumor immunity

Bhatt, K., Colombani, T., Nukovic, A., Parekh, N. A., Hamrangsekachaee, M., Rogers, Z. J., Sitkovsky, M. V., Hatfield, S. M., & Bencherif, S. A. (2026) · Cell Biomaterials · doi:10.1016/j.celbio.2026.100417 · Cited by 1 · see citing works

Reprogramming CAR T cells across genetic, epigenetic, metabolic and microenvironmental axes to improve efficacy and safety in cancer and autoimmune disease

Scherlinger, M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1806459 · Cited by 1 · see citing works

Editorial overview: Cancer 2020 current mechanistic insights into the hypoxia-adenosine-A2A adenosinergic immunosuppressive axis in cancer immunotherapies

Beavis, P. A., & Hatfield, S. M. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.10.012 · Cited by 1 · see citing works

Potentiating Cancer Immune Therapy via Nanomaterials and Purinergic Signaling

Ferrari, D., Gessi, S., Merighi, S., Nigro, M., Travagli, A., & Burns, J. S. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.893709

Eliminating the hypoxia driven immunosuppression in tumors to enable immunotherapies of cancer

Halpin-Veszeleiova, K. (2022) · doi:10.17760/d20455931

Data from Arginase 1–Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize with Anti–PD-1 Checkpoint Blockade

Jørgensen, M. A., Ugel, S., Hübbe, M. L., Carretta, M., Perez-Penco, M., Weis-Banke, S. E., Martinenaite, E., Kopp, K., Chapellier, M., Adamo, A., et al. (2023) · doi:10.1158/2326-6066.c.6550574.v1

Oxygen carrying nanoemulsions and respiratory hyperoxia eliminate tumor hypoxia-induced suppression and improve cancer immunotherapyPreprint

Halpin-Veszeleiova, K., Mallouh, M. P., Apro, A. C., Romero, N., Bahr, C., Shin, M., Ward, K., Rosenberg, L., Sitkovsky, M. V., Spiess, B. D., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.17.580835

Design and characterization of multiplex gene-edited CAR-T cells resistant to orthogonal immunosuppressive pathways within the solid tumor microenvironment

Murray, R. C. (2024) · doi:10.17760/d20653008

Additional file 1 of HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy

Hussain, K., Liu, R., Smith, R. C. G., Müller, K. T. J., Ghorbani, M., Macari, S. A., Cleary, K. L. S., Oldham, R. J., Foxall, R. B., James, S., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19549638

Oxygen-generating cryogel vaccines help overcome tumor antigen tolerance and induce durable antitumor immunity in prostate cancer

Nukovic, A., Bhatt, K., Colombani, T., Todorovic, E., Williamson, L. M., Noonan, B., Chang, E. M., Miguéns, L. L., Sitkovsky, M. V., Bencherif, S. A., et al. (2026) · Cell Biomaterials · doi:10.1016/j.celbio.2026.100578

Block, clear, and boost: a novel therapeutic framework for targeting intercellular mitochondrial transfer in Cancer immunotherapy

Liu, R., Yang, Y., Wang, Z., Hu, Z., Yang, L., Guo, R., & Wang, H. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.117027

Immunological mechanisms of the antitumor effects of supplemental oxygenation

Hatfield, S. M., Kjaergaard, J., Lukashev, D., Schreiber, T. H., Belikoff, B., Abbott, R., Sethumadhavan, S., Philbrook, P., Ko, K., Cannici, R., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa1260 · Cited by 600 · see citing works

Mechanistic Justifications of Systemic Therapeutic Oxygenation of Tumors to Weaken the Hypoxia Inducible Factor 1α-Mediated Immunosuppression

Hatfield, S. M., Halpin-Veszeleiova, K., Steingold, J., Sethuraman, J., & Sitkovsky, M. V. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-12734-3_8 · Cited by 30 · see citing works

Oxygen carrying nanoemulsions and respiratory hyperoxia eliminate tumor hypoxia-induced suppression and improve cancer immunotherapyPreprint

Halpin-Veszeleiova, K., Mallouh, M. P., Apro, A. C., Romero, N., Bahr, C., Shin, M., Ward, K., Rosenberg, L., Sitkovsky, M. V., Spiess, B. D., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.17.580835

Sufficient numbers of anti-tumor T cells is a condition of maximal efficacy of anti-hypoxia-A2-adenosinergic drugs during cancer immunotherapy

Sitkovsky, M. V. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.07.011 · Cited by 14 · see citing works

Oxygen-carrying nanoemulsions and respiratory hyperoxia eliminate tumor hypoxia–induced immunosuppression

Halpin-Veszeleiova, K., Mallouh, M. P., Williamson, L. M., Apro, A. C., Botticello-Romero, N. R., Bahr, C., Shin, M., Ward, K. M., Rosenberg, L., Ritov, V. B., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.174675 · Cited by 22 · see citing works